

## Mestag: Attacking tumors from within

BY RICHARD GUY, BIOPHARMA ANALYST

Immunology company Mestag believes that fibroblasts have been long overlooked as therapeutic targets and can be leveraged to treat cancer and inflammatory diseases. The company has raised \$45 million and presented data for its lead program to treat solid tumors at AACR.

CEO Susan Hill told BioCentury that Cambridge, U.K.-based Mestag Therapeutics Ltd. was founded by a group of

# BIOCENTURY

# BIOCENTURY

them to treat degenerative disc disease and multiple sclerosis, and for diabetic wound care. However, in contrast to Mestag, FibroBiologics is using fibroblasts to create cell-based therapies that can be administered topically or by injection, and not to manipulate the immune system.

Mestag launched in April 2021 with \$11 million in seed funding from founding investors SV Health Investors and Johnson & Johnson Innovation – JJDC. This seed round was extended to \$45 million the following August. Forbion led the extension, with participation from GV and Northpond Ventures, and both founding investors.

## COMPANY PROFILE

Mestag Therapeutics Ltd.

Cambridge, U.K.

Technology: